Get the Stockscreener App
3.10
5.20%
-0.17
After Hours:
3.24
0.14
+4.52%
Onkure Therapeutics Inc stock is traded at $3.10, with a volume of 98,719.
It is down -5.20% in the last 24 hours and up +14.39% over the past month.
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research.
See More
Previous Close:
$3.27
Open:
$3.26
24h Volume:
98,719
Relative Volume:
0.89
Market Cap:
$39.81M
Revenue:
-
Net Income/Loss:
$-70.20M
P/E Ratio:
-0.0692
EPS:
-44.82
Net Cash Flow:
$-50.66M
1W Performance:
-6.91%
1M Performance:
+14.39%
6M Performance:
+24.00%
1Y Performance:
-81.00%
1-Day Range:
$3.019
$3.31
1-Week Range:
$3.019
$3.50
52-Week Range:
$1.70
$17.74
Onkure Therapeutics Inc Stock (OKUR) Company Profile
Name
Onkure Therapeutics Inc
Sector
Industry
Phone
(720) 307-2892
Address
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Compare OKUR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
3.10 | 44.24M | 0 | -70.20M | -50.66M | -44.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-30-25 | Initiated | Evercore ISI | Outperform |
| Dec-05-24 | Initiated | Leerink Partners | Outperform |
| Oct-10-24 | Initiated | Oppenheimer | Outperform |
| Dec-15-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-15-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-14-23 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-23 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Dec-14-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-14-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-14-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-15-23 | Initiated | William Blair | Outperform |
| Aug-28-23 | Initiated | H.C. Wainwright | Buy |
| Jul-03-23 | Initiated | BofA Securities | Buy |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Jan-27-22 | Initiated | Robert W. Baird | Outperform |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-22-21 | Initiated | Ladenburg Thalmann | Buy |
| May-04-21 | Initiated | Jefferies | Buy |
| May-04-21 | Initiated | Piper Sandler | Overweight |
| May-04-21 | Initiated | SVB Leerink | Outperform |
View All
Onkure Therapeutics Inc Stock (OKUR) Latest News
OnKure Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
OnKure Therapeutics (NASDAQ: OKUR) to present at Guggenheim, Stifel, Evercore; webcasts - Stock Titan
How to read the order book for OnKure Therapeutics Inc.Portfolio Value Summary & Growth Oriented Trade Recommendations - newser.com
Is OnKure Therapeutics Inc. stock ready for a breakoutWatch List & Entry Point Confirmation Signals - newser.com
Custom watchlist performance reports with OnKure Therapeutics Inc.2025 Year in Review & Long-Term Capital Growth Ideas - newser.com
Will OnKure Therapeutics Inc. stock remain a Wall Street favoriteWeekly Market Outlook & Accurate Entry/Exit Alerts - newser.com
Institutional scanner results for OnKure Therapeutics Inc.2025 Risk Factors & Daily Profit Maximizing Tips - newser.com
How OnKure Therapeutics Inc. stock reacts to inflationary pressuresProfit Target & Risk Managed Investment Strategies - newser.com
Onkure Therapeutics Inc expected to post a loss of $1.20 a shareEarnings Preview - TradingView
Is it time to cut losses on OnKure Therapeutics Inc.Portfolio Update Summary & Daily Stock Trend Watchlist - newser.com
OnKure Therapeutics Inc.’s volatility index tracking explainedGold Moves & Short-Term Trading Alerts - newser.com
What valuation multiples suggest for OnKure Therapeutics Inc. stockWeekly Market Outlook & Expert Curated Trade Setups - newser.com
Will OnKure Therapeutics Inc. stock continue upward momentumWeekly Loss Report & Free Growth Oriented Trading Recommendations - newser.com
What momentum shifts mean for OnKure Therapeutics Inc.Earnings Recap Summary & Growth-Oriented Investment Plans - newser.com
Analyzing drawdowns of OnKure Therapeutics Inc. with statistical toolsIPO Watch & Target Return Focused Stock Picks - newser.com
OnKure Therapeutics, Inc. (NASDAQ:OKUR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
How rising interest rates impact OnKure Therapeutics Inc. stockJuly 2025 Short Interest & Risk Controlled Daily Plans - newser.com
Can you recover from losses in OnKure Therapeutics Inc.2025 Pullback Review & Risk Controlled Daily Plans - newser.com
How OnKure Therapeutics Inc. stock compares to market leadersWeekly Stock Summary & AI Forecast Swing Trade Picks - newser.com
Is OnKure Therapeutics Inc. stock affected by interest rate hikesExit Point & Safe Entry Zone Identification - fcp.pa.gov.br
Will OnKure Therapeutics Inc. stock continue dividend increases2025 Growth vs Value & Detailed Earnings Play Strategies - fcp.pa.gov.br
Can OnKure Therapeutics Inc. stock maintain growth trajectory2025 Dividend Review & Daily Oversold Bounce Ideas - fcp.pa.gov.br
How strong is OnKure Therapeutics Inc. stock revenue growth2025 Earnings Impact & Proven Capital Preservation Tips - fcp.pa.gov.br
Onkure Therapeutics Inc Stock (OKUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):